Company intelligence / Profile preview
Sprout Pharmaceuticals
Raleigh, North Carolina, United Statessproutpharma.com ↗
- Ownership
- Private
- Employees
- ~31
- Development stage
- Other
01
Overview
Sprout Pharmaceuticals developed Addyi (flibanserin), the first FDA-approved drug for treating hypoactive sexual desire disorder in premenopausal women. The company achieved FDA approval and commercial launch but has faced ongoing controversy regarding efficacy and marketing practices. Addyi remains the company's flagship product.
- Therapeutic areas
- Women's Health
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major current pharmaceutical partnerships disclosed; previously acquired by Valeant Pharmaceuticals International [now Bausch Health], which was a key relationship during that period.
Beyond the preview
Go deeper on Sprout Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sprout Pharmaceuticals.